Find a Doctor
Monica S. Chatwal, MD
Specialty: Medical Oncology
Program: Satellite and Community Oncology
Locations: Moffitt Cancer Center at International Plaza
Cancer Types Treated: Bladder Cancer , Kidney (Renal Cell) Cancer , Prostate Cancer , Testicular Cancer
Dr. Chatwal earned her MD at Florida State University School of Medicine. She completed her Internal Medicine Residency at Emory University School of Medicine, followed by a Hematology Oncology Fellowship at Moffitt Cancer Center and the University of South Florida Morsani College of Medicine. Dr. Chatwal’s clinical focus is the medical oncology management of patients with genitourinary malignancies, though she also brings to the practice her experience and interest in other solid malignancies. Her research focus will include clinical trials and outcomes in genitourinary malignancies. Dr. Chatwal also has a practical and research interest in the important issue of provider burnout. She has published data on approaches to improve individual resiliency, and will explore both individual and system-dependent approaches to help combat and alleviate this ongoing issue.
Education & Training
CLINICAL TRIAL 19082
A Phase I/Ib Trial of Pirfenidone Combined with Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Intervention: Alimta (Pemetrexed); Paraplatin (carboplatin); Pemetrexed; Pirfenidone; Taxol (paclitaxel); carboplatin; paclitaxel
CLINICAL TRIAL 19874
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Intervention: BMS-936558 (Nivolumab); Lirilumab; Nivolumab
CLINICAL TRIAL 19988
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
- Chatwal MS, Tanvetyanon T. Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S208-S210. Pubmedid: 30393603. Pmcid: PMC6193911.
- Chatwal MS, Tanvetyanon T. Malignant mesothelioma clinical trial combines immunotherapy drugs. Immunotherapy. 2018 04;10(5):341-344. Pubmedid: 29473471.
- Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents. Expert Rev Respir Med. 2017 Oct;11(10):791-805. Pubmedid: 28786318.